KLF4 is a therapeutically tractable brake on fibroblast activation that promotes resolution of pulmonary fibrosis
Loka R. Penke(University of Michigan), Marc Peters‐Golden(Michigan Medicine)
Cited by 36
Related Papers
Formation, Signaling and Occurrence of Specialized Pro-Resolving Lipid Mediators—What is the Evidence so far?
|Frontiers in Pharmacology|2022|187
Leukotriene B<sub>4</sub>antagonism ameliorates experimental lymphedema
|Science Translational Medicine|2017|169
Hypermethylation of PTGER2 Confers Prostaglandin E2 Resistance in Fibrotic Fibroblasts from Humans and Mice
|American Journal Of Pathology|2010|141
Leukotriene B4 amplifies NF-κB activation in mouse macrophages by reducing SOCS1 inhibition of MyD88 expression
|Journal of Clinical Investigation|2011|139
FOXM1 is a critical driver of lung fibroblast activation and fibrogenesis
|Journal of Clinical Investigation|2018|128